Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' p... Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. 더 보기
– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b...
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.73 | -6.4089347079 | 58.2 | 58.91 | 52.09 | 642007 | 54.27182405 | CS |
4 | 10.47 | 23.7954545455 | 44 | 62.58 | 43.25 | 737033 | 52.768452 | CS |
12 | 8.86 | 19.4255645692 | 45.61 | 62.58 | 39.94 | 577738 | 48.18340399 | CS |
26 | 21.36 | 64.5122319541 | 33.11 | 62.58 | 31 | 639236 | 45.65238234 | CS |
52 | 32.73 | 150.551977921 | 21.74 | 62.58 | 20.96 | 677361 | 36.1582927 | CS |
156 | 16.16 | 42.1821978596 | 38.31 | 62.58 | 16.75 | 607944 | 30.17551217 | CS |
260 | 17.57 | 47.6151761518 | 36.9 | 62.58 | 16.75 | 639310 | 37.24425967 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관